Association of Mirabegron With the Risk of Arrhythmia in Adult Patients 66 Years or Older-A Population-Based Cohort Study

Mina Tadrous; Rano Matta; Simon Greaves; Sender Herschorn; Muhammad M Mamdani; David N Juurlink; Tara Gomes

doi:10.1001/jamainternmed.2019.2011

Association of Mirabegron With the Risk of Arrhythmia in Adult Patients 66 Years or Older-A Population-Based Cohort Study

JAMA Intern Med. 2019 Oct 1;179(10):1436-1439. doi: 10.1001/jamainternmed.2019.2011.

Authors

Mina Tadrous^{1

2

3

4}, Rano Matta^{2

5

6}, Simon Greaves², Sender Herschorn^{5

7}, Muhammad M Mamdani^{2

3

6

8}, David N Juurlink^{2

6

7}, Tara Gomes^{2

3

4

6}

Affiliations

¹ Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
² Institute for Clinical Evaluative Sciences (ICES), Toronto, Ontario, Canada.
³ Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
⁴ Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.
⁵ Division of Urology, University of Toronto, Toronto, Ontario, Canada.
⁶ Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
⁷ Sunnybrook Research Institute, Toronto, Ontario, Canada.
⁸ Li Ka Shing Centre for Healthcare Analytics Research and Training, St Michael's Hospital, Toronto, Ontario, Canada.

Abstract

This population-based cohort study evaluates the risk of cardiac arrhythmia and other cardiovascular events in patients 66 years or older receiving the β3-adrenoceptor agonist mirabegron.